Response of EGFR-mutated pulmonary pleomorphic carcinoma to pembrolizumab

Response of EGFR-mutated pulmonary pleomorphic carcinoma to pembrolizumab

Pulmonary pleomorphic carcinoma (PPC) is a rare and aggressive lung malignancy with limited treatment options. While immune checkpoint inhibitors (ICIs) have shown promise in treating PPC, evidence regarding their efficacy in epidermal growth factor receptor (EGFR)-mutated cases remains scarce. We r...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuki Hatakeyama, Hidenori Mizugaki, Noriyuki Yamada, Yasushi Mizukami, Ken Kuwahara, Hajime Asahina, Hirofumi Adachi, Hiroshi Yokouchi, Yoshihiro Matsuno, Satoshi Oizumi
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Pleomorphic carcinoma
EGFR mutation
Pembrolizumab
Immunotherapy
PD-L1
Osimertinib
Online Access:http://www.sciencedirect.com/science/article/pii/S221300712500070X
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items